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a b s t r a c t
Between September 2009 and May 2014 the classiﬁcation of 36 patients with cardiac
implantable electronic devices (CIEDs) in terms of the feasibility of MRI scanning due to
strong clinical indications was carried out. Finally MRI examinations were performed in 20
patients, of whom 27 studies were conducted and a total number of 35 anatomical regions
were scanned. Neurological, neurosurgical and neuro-oncology indications for MRI were
reported in 19 patients (95%) in whom 26 MRI studies (96.3%) were performed, and 34
anatomical regions (97.1%) were scanned. One patient had indications for MRI in the ﬁeld of
cardiology.
Medical information obtained from 27 MRI studies allowed decisions to be made regard-
ing the treatment in all patients. After 8 studies (29.6%), patients were classiﬁed into 9
different neurosurgical procedures. In the case of the remaining 19 studies (70.4%), there
were no indications for surgical treatment and the decisions to implement conservative
treatment were made.
There were no complications related to the implanted CIEDs observed: neither immedi-
ate nor in the follow-up.
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Conclusions:
(1) Magnetic resonance imaging studies in patients with non-MRI-conditional CIEDs in the
vast majority are performed because of signiﬁcant neurological, neurosurgical and
neuro-oncology clinical indications.
(2) Careful determination of the indications for MRI in each case allows the data necessary
to be obtained to make deﬁnitive treatment decisions.
(3) The adherence to examination protocol and device controlling procedures after MRI
allows a very high safety proﬁle of the method to be achieved.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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Magnetic resonance imaging (MRI) in patients with cardiac
implantable electronic devices (CIEDs) may be considered
when there are signiﬁcant clinical indications but in practice it
is usually avoided.
Magnetic resonance imaging is used in an increasing
number of indications, particularly when other imaging
techniques are insufﬁcient to help reach ﬁnal therapeutic
decisions. It is the method of choice in diagnosing many
disorders of the central nervous system. There is non-ionizing
radiation during the MRI scans so it is a preferable method in
patients who have indications for multiple MRI scanning.
In general awareness, cardiac implantable electronic
devices (CIEDs) are considered a strong contraindication to
conduct MRI examination.
The American Heart Association (AHA) and the American
College of Radiology (ACR) developed in 2007 the position
regarding the conditional execution of MRI in patients with
CIEDs and emphasized that the eligibility of a patient with the
implanted device must be always determined to estimate the
risk–beneﬁt ratio, and the presence of CIED is therefore a
relative contraindication to MRI [1]. The Recommendations of
The European Society of Cardiology (ESC) on Cardiac Pacing
and Cardiac Resynchronization Therapy published in 2013 and
created in collaboration with the European Heart Rhythm
Association (EHRA) allow the possibility of MRI scan execution
in patients with implanted devices [2]. In the case of
‘‘traditional pacemakers’’ [not certiﬁed for MRI or MRI ()]
the recommendation is class level IIb and has level of
evidence: C, if there is a presence of signiﬁcant clinicalTable 1 – Classes of recommendations.
Classes of
recommendations
Deﬁnition 
Class I Evidence and/or general agreement that a g
is beneﬁcial, useful, effective
Class II Conﬂicting evidence and/or a divergence of
usefulness/efﬁcacy of the given treatment 
Class IIa Weight of evidence/opinion is in favor of u
Class IIb Usefulness/efﬁcacy is less well established 
Class III Evidence or general agreement that the giv
not useful/effective, and in some cases maindications for MRI. However, in the case of the newer types of
devices with a safety proﬁle, certiﬁed for the MRI environment
[MRI (+)], the recommendation is class level IIa and has level of
evidence: C, assuming compliance with recommendations of
the device manufacturer. Classes of Recommendations and
the Levels of Evidence are shown in Tables 1 and 2.
The vast majority of patients in Poland and throughout the
world, have traditional devices [MRI ()] and as such are still
excluded from the beneﬁts arising from the MRI. At the same
time statistics show that up to 50–75% of patients after CIED
implantation will develop the indications for MRI scanning in
their lifetimes [3]. Physicians may need MRI examination for
17% of their patients within twelve months after pacemaker
implantation [4]. Due to the increasing number of patients
with implanted CIED, this situation constitutes a very serious
diagnostic limitation.
MRI scans in patients with CIED and with signiﬁcant clinical
indications were initiated in our department in 2009.
We are showing our own experience in the conducting of
MRI examination in patients with CIED, analysis of indications
spectrum and the utility of MRI results in making ﬁnal
therapeutic decisions.
2. Aim of the study
Evaluation of the possibility to take the deﬁnitive therapeutic
decisions based on the result of MRI 1.5 T in patients with
cardiac implantable electronic devices and with signiﬁcant
indications for MRI.Suggested wording to use
iven treatment or procedure Is recommended/is indicated
 opinion about the
or procedure
sefulness/efﬁcacy Should be considered
by evidence/opinion May be considered
en treatment or procedure is
y be harmful
Is not recommended
Table 2 – Levels of evidence.
Level of evidence A Data derived from multiple randomized
clinical trials or meta-analyses
Level of evidence B Data derived from a single randomized
clinical trial or large non-randomized
studies
Level of evidence C Consensus of opinion of the experts
and/or small studies, retrospective
studies, registries
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In the years 2009–2014 examinations using MRI were per-
formed in 20 patients with CIED (12 men, 8 women), with the
mean age of 69.5 years (from 52 to 88 years). All patients had
signiﬁcant clinical indications for testing by means of
magnetic resonance imaging and other diagnostic methods
were not sufﬁcient to make the ﬁnal therapeutic decision.
4. Methods
Patients for MRI studies were mostly referred to our depart-
ment by neurologists, neurosurgeons and oncologists. Then a
consultation carried out by a cardiologist and radiologist (CIED
MRI Team – CMT) was done. Only on the basis of such a
consultation was the ﬁnal qualiﬁcation for MRI made. In some
doubtful cases direct consultations between CMT and a
neurologist, neurosurgeon or oncologist as a referring physi-
cian were needed. Each negative decision was discussed with a
referring physician. In the process of qualiﬁcation for the MRI
examination the clinical relevance of the proposed examina-
tion and the possibilities of alternative diagnostic techniques
were determined by the CMT. The comparison of the
predictable beneﬁts and the potential risks arising from the
presence of the implanted system in the electromagnetic ﬁeld
was discussed. In order to guarantee safety during the
implementation of the MRI, the patients were hospitalized
for three days. During hospitalization electrocardiogram,
echocardiogram, at least 3 controls of the device and basic
laboratory tests were performed.
The types of CIEDs owned by patients are shown in Table 3.
All patients' devices belonged to the category of non-approved
for the use in the electromagnetic environment [MRI ()],
except for one pacemaker approved for the use in the
electromagnetic environment [MRI (+)]. But this pacemakerTable 3 – Types of devices implanted in studied patients.
Pacemaker 17 (85%)
VVI 4 (20%)
AAI 2 (10%)
DDD 11 (55%)
Included pacemaker dependent patients 4 (20%)
Implantable cardioverter deﬁbrillator 1 (5%)
Implantable loop recorder 2 (10%)
Abbreviations: VVI, ventricular pacemaker; AAI, atrial pacemaker;
DDD, atrio-ventricular sequential pacemaker.was connected to the leads MRI () and due to that fact this
whole device was regarded as the MRI ().
Immediately before performing the MRI scans, CIEDs were
suitably, temporarily programmed. The basic parameters such
as: battery impedance, battery voltage, level of battery charge,
lead impedance, pacing threshold and sensing were checked.
If a patient had his own rhythm the AAI, VVI or DDI mode was
programmed. If a patient was pacemaker dependent, the AOO,
VOO or DOO mode was programmed. MRI examinations were
performed on a Siemens Avanto 1.5 T MRI scanner. Speciﬁc
absorption rate (SAR) was limited to <2.0 W/kg. SAR is a
measure of the rate at which energy is absorbed by the body
when exposed to a radio-frequency electromagnetic ﬁeld. It is
deﬁned as the power absorbed per mass of tissue and has units
of watts per kilogram (W/kg). The time of each study was not
limited. The patient's safety and the proper conduct of MRI
examination were supervised by CMT. While conducting the
MRI scan, the heart rate, blood pressure, ECG and blood oxygen
saturation were monitored by means of a camera approved for
use in the electromagnetic environment.
When MRI scanning was ﬁnished, the implanted devices
were carefully checked and reprogrammed according to
settings present before the MRI. If there were no irregularities
in the functioning of the implanted device directly after the
MRI and for the following 24 h, and if there were no other
complications, patients were discharged from the hospital to
continue routine device checking as before as an outpatient.
MRI data were sent to the physician who referred the patient to
the test.
We analyzed the ﬁnal form of the therapy based on the data
from the MRI studies.
5. Results
Between September 2009 and May 2014, 36 patients with CIEDs
were consulted in terms of the possibility to undergo magnetic
resonance imaging. Finally, 20 patients who had important
indications were qualiﬁed for MRI. Sixteen patients were not
qualiﬁed for MRI. The main reason was that patients after
being informed about the possible risk decided not to undergo
MRI scanning (11 patients). In 4 cases there were alternative
imaging techniques suggested (Computed Tomography). In the
case of one patient with epicardial leads, in our opinion, the risk
of MRI scanning was too high. The patients who qualiﬁed for
MRI underwent a total number of 27 MRI studies (4 patients had
2 studies and 1 patient had 4 studies), during which 35
anatomical body regions were examined. The indications for
MRI in the ﬁeld of neurology, neurosurgery and neuro-oncology
were reported in 19 patients (95%) in whom 26 MRI studies (
96.3%) were conducted and 34 body regions (97.1%) were
scanned. The types of indications, number of patients and
number of studies are shown in Table 4.
Among the performed tests the majority were those
relating to one body area. The following were also performed:
3 studies of 2 anatomical regions (spine Th and LS regions), one
study involving 3 anatomical regions (spine C, Th and LS
regions) and one study involving 4 body areas (head, spine C,
Th and LS regions). The number of anatomical areas is
summarized in Table 5.
Table 5 – MRI studies detailing anatomical areas scanned.
Anatomical areas scanned n
MRI of head 15
MRI of spinal column
Cervical 6
Thoracic 5
Lumbosacral 7
MRI of heart 1
MRI of pelvis 1
Total 35
Table 4 – Indications for MRI, number of patients, number
of examinations for each indication.
Indications for MRI Patients MRI
examination
Movement/sensory disorders
of upper limbs
3 3
Movement/sensory disorders
of lower limbs
9 9
Brain tumor 3 9
Encephalitis 1 1
Cerebral aneurysm 1 2
Motor aphasia 1 1
Syncopies of unknown, probable
central origin
1 1
Acute heart failure aggravation in
previously healthy young subject
1 1
Total 20 27
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determining the causes of the diseases as well as the
possibility of making a ﬁnal decision.
It was found, as a result of all independent MRI studies, that
it was possible to clearly establish the kind of therapeutic
treatment.
Twenty-seven of the MRI studies were performed, out of
which 26 (96.3%) were related to the issues on the borderline of
neurology, neurosurgery and neuro-oncology and one (3.7%)
study was done because of cardiology reasons (cardiac MRI in a
52-year-old woman with an acute heart failure). On the basis of
8 MRI studies (29.6%) 6 patients (30%) were classiﬁed into 9
different surgical procedures:
1. In the case of 3 patients, only once was a neurosurgical
treatment introduced. These were the procedures concern-
ing: brain tumor, herniated nucleus pulposus of interverte-
bral disc of the cervical spine and herniated nucleus
pulposus of intervertebral disc of the lumbar spine.
2. Two patients were directed to double-surgical treatment on
the basis of two separate MRI scans.Fig. 1 – Types of therapeutic decisions based on MRI. (For interp
reader is referred to the web version of this article.)a. The ﬁrst patient had two incidents of paraplegia caused by
herniations of the nucleus pulposus at different levels of the
thoracic spine, which appeared one by one at an interval of
18 months.
b. The second patient, with a brain tumor, after the ﬁrst MRI
examination was qualiﬁed for neurosurgical treatment. The
control MRI examination showed the incomplete resection
of the tumor and re-surgical treatment was planned.
3. Moreover, one patient was selected for two different
surgical procedures on the basis of one anatomical region
MRI scanning. Firstly, the treatment of vertebral angioma
Th 11 was performed. Secondly, the treatment of disc
herniation at spine level L5 – S1 was conducted.
Lastly, thanks to the data obtained in 19 studies (70.4%),
patients were eligible for medical management: observation of
changes, drug treatment, rehabilitation, and, in one case,
biological treatment of encephalitis. These proceedings con-
cerned 14 patients (70%). The distribution of therapeutic
decisions is shown in Fig. 1.
In Fig. 2, the MRI scan demonstrates the hyperintense
signal in the medial right temporal lobe and part of the right
insula in a man with limbic encephalitis and epilepsy. In Fig. 3,
the MRI scan demonstrates the hyperintense signal in the
medial right temporal lobe and hippocampus in the same
patient.retation of the references to colour in this figure legend, the
Fig. 2 – Coronal image from Fluid-Attenuated Inversion
Recovery (FLAIR) MRI. MRI scan demonstrates the
hyperintense signal in the medial right temporal lobe and
part of the right insula in a man with limbic encephalitis
and epilepsy.
Fig. 4 – Axial image from a contrast-enhanced MRI follow-
up of coiled aneurysm of the right middle cerebral artery.
MRI scan demonstrates partial central recanalization of the
aneurysm and the thin linear rim of peripheral/
circumferential contrast enhancement around the coil
mass, which is not representative of recanalization but
more likely of mural enhancement as a sequela of the in-
growth of granulation tissue.
Fig. 3 – Axial image from Fluid-Attenuated Inversion
Recovery (FLAIR) MRI. MRI scan demonstrates the
hyperintense signal in the medial right temporal lobe and
hippocampus in a man withlimbicencephalitis andepilepsy.
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whom as a new ﬁnding, brain tumors not shown previously in
other imaging studies were detected, should be given
additional attention. In the ﬁrst patient meningioma was
detected on MRI. The patient had an MRI taken as a control
study after embolization of the middle cerebral artery
aneurysm. As the ﬁrst step computed tomography was
conducted but it was disrupted by a large halo effect, so a
decision regarding MRI examination was made. The MRI test
result proved to be diagnostic for the assessment of aneurysm
treatment and additionally a meningioma was detected. In
this case the conservative treatment and observation of
changes were proposed. In the control MRI examination, after
18 months, there was no tumor growth observed. The MRI
scans of this patient are shown in Figs. 4–7.
The second patient had a tumor in the cererebellopontine
angle as a new ﬁnding. It was invisible in computed
tomography. This tumor was selected for surgical treatment
by the Cyber-Knife method. Six months later, the second MRI
study showed that the tumor was the same size as before the
cyber-knife surgery. After the second MRI no more surgical
treatment was implemented. Conservative treatment and
observation of changes were proposed.
Fig. 5 – Coronal image from a T1WI contrast-enhanced MRI.
MRI scan demonstrates infratentorially, well-
circumscribed, homogeneous enhanced mass, shaping left
cerebellar hemisphere. MR image is typical for
meningioma.
Fig. 6 – Sagittal image from a T1 weighted image (T1WI)
contrast-enhanced MRI. MRI scan demonstrates well-
circumscribed, homogeneous enhanced subtentorial mass
with a broad dural base. MR image was described to be
typical for meningioma.
Fig. 7 – Three-dimensional time of flight (TOF)-MRI source
image demonstrates partial recanalization of the of the
right middle cerebral artery aneurysm, treated using a coil
embolization technique.
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presence under the inﬂuence of electromagnetic ﬁeld.
6. Discussion
The presented data show that the indications for MRI in the
ﬁeld of neurology, neurosurgery and neuro-oncology are in the
vast majority. All patients eligible to scanning had signiﬁcant
clinical indications for MRI, and other previously conducted
imaging tests had not revealed the cause of ailments. The
CIEDs owned by these patients met safety requirements to
justify taking the risk connected with a MRI examination.
In the cases of all patients it was possible to identify the
cause of therapeutic problems and to take appropriate
treatment on the basis of MRI examinations.
Patients not eligible for MRI scanning in the majority did
not agree to examination because of the possible risks. Such
situations mostly appeared at the beginning of our program, in
the years 2009–2011, when our experience was not extensive
enough and there was little information from other sources
about performing MRI scans in patients with CIEDs.
We believe that taking well-considered risks of procedure
for the implementation of MRI in patients with CIEDs is
justiﬁed to achieve the therapeutic target.
It should be emphasized that the qualifying of patients for
MRI examination more than once was caused each time by a
new clinical situation or by the progression of the disease. In
such a situation, patients were subjected to a new, indepen-
dent qualiﬁcation for the MRI procedure. Qualiﬁcation for the
MRI in the same patients did not result from the inability to
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previous MRI. Other qualiﬁcations were always caused by the
progression of the disease or the need to monitor the results of
treatment.
It is very important that a team consisting of a cardiologist
and radiologist who are in contact with a referring physician
should evaluate on each occasion the clinical relevance of the
proposed research, the possibility of using the alternative
diagnostic techniques, and should always deﬁne potential
risks associated with the implanted device undergoing MRI
scans. In the present work, the lack of qualiﬁcations for MRI in
16 patients, out of 36 originally reported to consider the MRI
study, was due to the lack of patients' consent, the possibility
of using alternative imaging methods, not sufﬁciently strong
indications or signiﬁcantly increased risk associated with the
device (for example the presence of epicardial leads).
More and more centers perform MRI studies in patients
with CIEDs. Both, patients with pacemakers [5–13] and
implantable cardioverter-deﬁbrillators [14–19] underwent
MRI examinations. This phenomenon is inevitable. The main
reason is that year-by-year more patients are treated by using
CIEDs. Indications for MRI are still multiplying and probably
this trend will continue. Such a situation requires searching for
new solutions. One of the best solutions is a device certiﬁed for
MRI. But in our population this rarely occurs. We have to learn
how to help patients with CIEDs non-certiﬁed for MRI.
As regards patients with CIEDs, the information gained
from MRI is very valuable, because the indications were well
considered. We believe that MRI studies in patients with CIEDs
are probably more diagnostic than in patients without pace-
makers. This is because indications for MRI in patients without
CIEDs are sometimes borderline.
At present, the CIEDs certiﬁed for MRI [MRI (+)] are
increasingly available. These new pacemakers and ICDs were
tested in the MRI environment [20–25]. In the group described
in the article only one patient had an MRI (+) pacemaker
implanted but it was connected to the non-MRI certiﬁed leads
and the entire system was also considered as non-certiﬁed for
MRI [MRI ()]. Patients with a complete device system certiﬁed
for MRI (device and leads) have a reduced risk of complications
during MRI, but there is no guarantee of complete security.
Therefore, the calculation of anticipated beneﬁts and potential
risks arising from the implementation of MRI regardless of the
device type [MRI (+), MRI ()] is always necessary and the
detailed analysis of the manufacturers' instructions should
not be neglected. It should be mentioned that there is a
possibility of extraction of non-MRI Conditional CIED to
facilitate scanning. According to The Heart Rhythm Society
Consensus on Lead Extraction, this kind of procedure is in
Class IIb of recommendations and has level of evidence: C [26].
The results of this study relate only to patients with
‘‘classic’’ CIEDs that are not certiﬁed for performing MRI. Not
all manufacturers of CIEDs and not all types of devices were
represented. It should be noted that all manufacturers are
emphasizing contraindications to MRI. These are included in
the instruction manuals of traditional CIEDs. Therefore, the
increasing use of MRI-compatible devices is indicated and
probably in the next few years it should become the ‘‘gold
standard’’ for this method of treatment. It should be noted that
regardless of the CIED type [MRI (+) or MRI ()], performing ofMRI may be considered in every case, as far as the health and
life of the patient requires it, but only after the exact
calculation of beneﬁts and risks.
7. Conclusions
(1) Magnetic resonance imaging studies in patients with
cardiac implantable electronic devices not certiﬁed for
MRI are performed in the vast majority because of
signiﬁcant clinical indications in the ﬁeld of neurology,
neurosurgery and neuro-oncology.
(2) Careful determination of the indications for MRI in each
case allows to obtain the data necessary to make deﬁnitive
treatment decisions.
(3) The adherence to examination protocol and device
controlling procedures after MRI allows to achieve a very
high safety proﬁle of the method.
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